BY: WITHUM
On April 22, 2026, the U.S. Department of Justice (DOJ), through the Drug Enforcement Administration (DEA), issued a final order rescheduling certain marijuana-related products from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). While this action is limited in scope, it carries significant regulatory and federal tax implications, particularly for state-licensed medical marijuana businesses and companies with FDA-approved cannabis-derived products. This is a meaningful step toward federal normalization of medical marijuana, but it is not decriminalization, and it does not remove marijuana from Schedule I in all circumstances.
Key Takeaways
The DOJ rescheduling represents a partial federal normalization of medical marijuana, not decriminalization.
The most immediate and meaningful impact is federal income tax relief for medical marijuana operators.
Operators holding only recreational licenses remain fully subject to Section 280E; businesses with both medical and recreational licenses face a more complex analysis. The Treasury is expected to issue guidance on allocating expenses under for dual license operators.
WHAT CHANGED
The DEA’s final order places the following into Schedule III of the CSA:
- FDA-approved drug products containing marijuana.
- Marijuana, marijuana extracts and naturally derived delta-9-THC, but only when included in an FDA-approved drug product or handled pursuant to a qualifying state-issued medical marijuana license.
The DEA also amended its regulations to preserve import and export permit requirements, maintaining U.S. compliance with international treaty obligations.
WHAT DID NOT CHAGE
The following remain Schedule I controlled substances under federal law:
- Unlicensed bulk marijuana, marijuana crops and raw plant material
- Marijuana used outside of FDA approval or state medical licensing programs
- Synthetic cannabinoids, such as delta-10 THC
- Recreational marijuana, regardless of state legalization status
- Hemp, which is excluded from the definition of marijuana under federal law
Federal Tax Implications: Section 280E
he most immediate financial impact of this rescheduling is on federal taxes. Following the DOJ’s final order, Treasury and the IRS have announced that they plan to issue formal guidance addressing the principal federal tax issues stemming from the rescheduling action. Three key points from that announcement stand out for cannabis operators.
- 280E relief is confirmed for qualifying businesses. Rescheduling removes the applicability of Section 280E with respect to state medical licensed operators.
- For operators with both medical and recreational licenses, we are expecting forthcoming guidance to clarify how to allocate expenses that remain subject to Section 280E. This is significant because it signals that tax relief will not require full structural separation of medical and recreational operations.
Later in the day on April 23, 2026, the Treasury announced that the effective date of rescheduling for those eligible will be January 1, 2026. A transition rule is expected. Businesses should factor this into their current year tax planning and estimated payment calculations.
Regulatory Impact on Operators
- FDA-Approved Product Manufacturers and Distributors: Entities handling marijuana exclusively in FDA-approved drug products must now comply with Schedule III requirements, including DEA registration, prescription and dispensing controls, and recordkeeping, security, labeling, and inventory rules.
- State-Licensed Medical Marijuana Operators: The DEA has established a new expedited federal registration pathway for state-licensed medical marijuana manufacturers, distributors, and dispensers. Under this framework, state licenses serve as conclusive evidence of state authorization, federal oversight is streamlined and coordinated with existing state regulatory systems, and DEA registration is automatically suspended if the underlying state license lapses.
This cooperative federal-state regulatory approach reflects a significant shift in how the federal government engages with state-licensed medical marijuana markets, without constituting full federal legalization.
Withum’s Cannabis Services Team is actively assisting clients with 280E transition modeling and planning, evaluation of federal-state compliance obligations and structuring considerations following Schedule III placement. We will continue monitoring the situation as Treasury and the IRS issue further guidance. Please contact us if you would like to discuss how this development affects your business.
